Last Updated : February 19, 2025
Details
| Call for patient/clinician input open | February 27, 2024 |
|---|---|
| Call for patient/clinician input closed | April 22, 2024 |
| Clarification: - Patient input submission received from Transthyretin Amyloidosis Canada (TAC) | |
| Submission received | April 09, 2024 |
| Submission accepted | April 23, 2024 |
| Review initiated | April 24, 2024 |
| Draft CADTH review report(s) provided to sponsor for comment | July 10, 2024 |
| Deadline for sponsors comments | July 19, 2024 |
| CADTH review report(s) and responses to comments provided to sponsor | August 16, 2024 |
| Expert committee meeting (initial) | August 28, 2024 |
| Draft recommendation issued to sponsor | September 12, 2024 |
| Draft recommendation posted for stakeholder feedback | September 19, 2024 |
| End of feedback period | October 04, 2024 |
| Final recommendation issued to sponsor and drug plans | October 21, 2024 |
| Final recommendation posted | November 06, 2024 |
| Deadline for sponsor to submit redaction requests on draft CADTH review report(s) | November 04, 2024 |
| CADTH review report(s) posted | February 18, 2025 |